Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (13217)	9/30/2004 9:20:09 AM
From: Biomaven	Read Replies (3) of 52153

Well there was an interesting comment I heard a few weeks ago from a researcher specializing in the side effects of RA drugs - "I wouldn't give Vioxx to my dog." He thought the new Novartis drug might be the best of breed from a cardiac standpoint, although my understanding is the FDA has concerns about liver tox issues. I'm pretty impressed by MRK's actions here - not many companies would have done what they are doing. It's a devastating blow to them, and it's going to hurt all the pharmas - going to make people look skeptically at all the cox-2 drugs. Actually calls into question as to whether MRK can survive as an independent company. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next